Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics.

Our study improves the current understanding of PARP1 function, highlights the potential that the anti-tumor efficacy of PARP1i may not only rely on DNA damage repair mechanisms and informs on the rational design of PARP1i combination therapies in ovarian cancer.